Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CDK4/6 Inhibitors + Endocrine Therapy in HR+/HER2+ Early Breast Cancer
NCT07019363Phase 3Recruiting
- Sponsor
- Fudan University
- Start
- Jun 2025
- Primary completion
- May 2029
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in breast cancer (2 arms), sponsored by Fudan University. Primary endpoint: Invasive Disease-Free Survival at 5 years. Started Jun 2025; status: recruiting.
02
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07019363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07019363.